Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Genova Inc. (9341:JPX), powered by AI.
Genova Inc. is currently trading at ¥570. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Genova Inc. on Alpha Lenz.
Genova Inc.'s P/E ratio is 7.1.
“Genova Inc. trades at a P/E of 7.1 (undervalued) with strong ROE of 21.7%. 3Y revenue CAGR of 27.7% highlights clear growth momentum.”
Ask for details →Genova Inc. is a leading biotechnology company specializing in cutting-edge medical research and development. Its primary function is to innovate and produce therapeutic solutions targeting complex diseases, profoundly impacting the healthcare sector. Genova Inc. focuses on developing biologic treatments and personalized medicine, which are critical in treating cancers and rare genetic disorders. By leveraging advanced genetic engineering and molecular biology techniques, Genova plays a crucial role in the biopharmaceutical industry. The company's contributions extend to collaboration with research institutions and hospitals, aiming to advance scientific understanding and improve patient outcomes. Headquartered in a major biotech hub, Genova Inc.'s work not only advances medical science but also drives substantial economic growth within the life sciences sector. Its dedicated research efforts and partnerships further emphasize its significance in the global biotech market, making it a key player in the innovation and accessibility of high-impact medical therapeutics.
“Genova Inc. trades at a P/E of 7.1 (undervalued) with strong ROE of 21.7%. 3Y revenue CAGR of 27.7% highlights clear growth momentum.”
Ask for details →Genova Inc. (ticker: 9341) is a company listed on JPX in the Healthcare sector (Medical Devices). It has approximately 408 employees. Market cap is $10.1B.
The current price is 570 with a P/E ratio of 7.14x and P/B of 1.44x.
ROE is 21.69% and operating margin is 20.25%. Annual revenue is $10.0B.